Article/Intelligence
Thrive Pet Negotiating Pro Rata Deal With Lenders for New Money
Thrive Pet Healthcare is negotiating a potential pro rata deal with its lenders, who may provide fresh money to the company, according to sources.
A majority of lenders are in confidential talks with the TSG Partner-backed vet clinic chain that has been contending with higher labor costs and volume headwinds, Octus previously reported.
Moody’s Investors Service revised the company’s outlook to negative last year, citing potential debt restructuring or default because of weakening profitability and an unsustainable capital structure.
The company’s third-quarter adjusted EBITDA dropped 18% year over year to $32 million, which was 38% below budget. Revenue came in flat at $316 million, missing the budget by 7%, Octus previously reported.
An ad hoc group of lenders to the company is working with PJT Partners as investment banker and Akin Gump as legal advisor, Octus, formerly Reorg, reported. The vet clinic chain has engaged Ropes & Gray as legal advisor and Evercore as financial advisor, as reported.
An estimated capital structure of the company is below:
The company’s $1 billion first lien loan due 2027 was quoted at 81/82 today, according to Solve. CLO lenders are HERE.
Thrive Pet Healthcare and sponsor TSG Consumer Partners did not respond to requests for comment.
This publication has been prepared by Octus, Inc. or one of its affiliates (collectively, "Octus") and is being provided to the recipient in connection with a subscription to one or more Octus products. Recipient’s use of the Octus platform is subject to Octus Terms of Use or the user agreement pursuant to which the recipient has access to the platform (the “Applicable Terms”). The recipient of this publication may not redistribute or republish any portion of the information contained herein other than with Octus express written consent or in accordance with the Applicable Terms. The information in this publication is for general informational purposes only and should not be construed as legal, investment, accounting or other professional advice on any subject matter or as a substitute for such advice. The recipient of this publication must comply with all applicable laws, including laws regarding the purchase and sale of securities. Octus obtains information from a wide variety of sources, which it believes to be reliable, but Octus does not make any representation, warranty, or certification as to the materiality or public availability of the information in this publication or that such information is accurate, complete, comprehensive or fit for a particular purpose. Recipients must make their own decisions about investment strategies or securities mentioned in this publication. Octus and its officers, directors, partners and employees expressly disclaim all liability relating to or arising from actions taken or not taken based on any or all of the information contained in this publication. © 2025 Octus. All rights reserved. Octus(TM) and the Octus logo are trademarks of Octus Intelligence, Inc.